drugset / Trial / NCT03766295
Masitinib Plus Gemcitabine in Pancreatic Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.
Timeline
- Start
- 2014-07
- Primary completion
- 2020-12
- Completion
- 2020-12
Outcome
Met primary endpoint
release “its Phase 3 study (AB12 005 - NCT03766295) met its primary objective to demonstrate increase in survival in pancreatic cancer with pain.” ab-science.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 6 mg/kg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
Indications
No indication recorded.